NO304489B1 - Mikroorganisme for deteksjon av tetracyklin efflukspumpehemmere og anvendelse av mikroorganismen - Google Patents
Mikroorganisme for deteksjon av tetracyklin efflukspumpehemmere og anvendelse av mikroorganismen Download PDFInfo
- Publication number
- NO304489B1 NO304489B1 NO924705A NO924705A NO304489B1 NO 304489 B1 NO304489 B1 NO 304489B1 NO 924705 A NO924705 A NO 924705A NO 924705 A NO924705 A NO 924705A NO 304489 B1 NO304489 B1 NO 304489B1
- Authority
- NO
- Norway
- Prior art keywords
- tetracycline
- gene
- microorganism
- teta
- efflux pump
- Prior art date
Links
- 239000004098 Tetracycline Substances 0.000 title claims description 257
- 235000019364 tetracycline Nutrition 0.000 title claims description 257
- 150000003522 tetracyclines Chemical class 0.000 title claims description 255
- 229960002180 tetracycline Drugs 0.000 title claims description 242
- 229930101283 tetracycline Natural products 0.000 title claims description 242
- 244000005700 microbiome Species 0.000 title claims description 53
- 239000003112 inhibitor Substances 0.000 title claims description 33
- 238000001514 detection method Methods 0.000 title claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 106
- 230000014509 gene expression Effects 0.000 claims description 60
- 238000012360 testing method Methods 0.000 claims description 40
- 101150061166 tetR gene Proteins 0.000 claims description 25
- 230000012010 growth Effects 0.000 claims description 14
- 108700028369 Alleles Proteins 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 230000035945 sensitivity Effects 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 11
- 101150066555 lacZ gene Proteins 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- DDRCIGNRLHTTIW-UHFFFAOYSA-N n-(4-amino-2,5-dimethoxyphenyl)benzamide Chemical compound C1=C(N)C(OC)=CC(NC(=O)C=2C=CC=CC=2)=C1OC DDRCIGNRLHTTIW-UHFFFAOYSA-N 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 description 82
- 238000000034 method Methods 0.000 description 71
- NHKCCADZVLTPPO-UHFFFAOYSA-N desferrioxamine E Chemical compound ON1CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC1=O NHKCCADZVLTPPO-UHFFFAOYSA-N 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 51
- 150000001875 compounds Chemical class 0.000 description 33
- 108010066713 deferrioxamine E Proteins 0.000 description 27
- 230000006698 induction Effects 0.000 description 27
- 101150107585 tetA gene Proteins 0.000 description 26
- 230000005764 inhibitory process Effects 0.000 description 25
- 239000002609 medium Substances 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 24
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 23
- 230000001105 regulatory effect Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 19
- 230000000638 stimulation Effects 0.000 description 19
- 229940040944 tetracyclines Drugs 0.000 description 15
- 108091081024 Start codon Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000009036 growth inhibition Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 101100206300 Escherichia coli tetC gene Proteins 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 239000000589 Siderophore Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 7
- 241001288713 Escherichia coli MC1061 Species 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 101150118377 tet gene Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 235000019365 chlortetracycline Nutrition 0.000 description 4
- 101150022010 gam gene Proteins 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 229960004023 minocycline Drugs 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 101150117635 tetC gene Proteins 0.000 description 4
- 108010054278 Lac Repressors Proteins 0.000 description 3
- 241001625930 Luria Species 0.000 description 3
- 102000001218 Rec A Recombinases Human genes 0.000 description 3
- 108010055016 Rec A Recombinases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- -1 fusaric acid Chemical class 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 101150011498 lad gene Proteins 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- PPJYSSNKSXAVDB-UHFFFAOYSA-N 3,3',5,5'-tetraiodothyroacetic acid Chemical compound IC1=CC(CC(=O)O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 PPJYSSNKSXAVDB-UHFFFAOYSA-N 0.000 description 2
- 239000004099 Chlortetracycline Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- MTCQOMXDZUULRV-ADOAZJKMSA-N (4s,4as,5ar,12ar)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O MTCQOMXDZUULRV-ADOAZJKMSA-N 0.000 description 1
- XHCNINMOALIGKM-UHFFFAOYSA-N 5,5,7,12,12,14-hexamethyl-1,4,8,11-tetrazacyclotetradecane Chemical compound CC1CC(C)(C)NCCNC(C)CC(C)(C)NCCN1 XHCNINMOALIGKM-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101100398597 Botryotinia fuckeliana lcc1 gene Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 108010067157 Ferrichrome Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 101100068374 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) GIP1 gene Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000702208 Shigella phage SfX Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 101150113996 bet gene Proteins 0.000 description 1
- 238000002959 beta galactosidase induction Methods 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 101150034144 ci gene Proteins 0.000 description 1
- CWFRPHYKKQVWNI-HADAFWAXSA-N cinodine Chemical compound O([C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(N)=N)NC(=O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]3N(C(=O)N[C@H]3[C@H](O)CO2)C(N)=O)CO1)NC(N)=O)C)C1=CC=C(\C=C\C(=O)NCCCNCCCCN)C=C1.O([C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(N)=N)NC(=O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@H]3NC(=O)O[C@@H]3CO2)NC(N)=O)CO1)NC(N)=O)C)C1=CC=C(\C=C\C(=O)NCCCNCCCCN)C=C1 CWFRPHYKKQVWNI-HADAFWAXSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- GGUNGDGGXMHBMJ-UHFFFAOYSA-N ferrichrome Chemical compound [Fe+3].CC(=O)N([O-])CCCC1NC(=O)CNC(=O)CNC(=O)CNC(=O)C(CCCN([O-])C(C)=O)NC(=O)C(CCCN([O-])C(C)=O)NC1=O GGUNGDGGXMHBMJ-UHFFFAOYSA-N 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 101150045159 tetB gene Proteins 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 230000013715 transcription antitermination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80363491A | 1991-12-06 | 1991-12-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO924705D0 NO924705D0 (no) | 1992-12-04 |
| NO924705L NO924705L (no) | 1993-06-07 |
| NO304489B1 true NO304489B1 (no) | 1998-12-28 |
Family
ID=25187068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO924705A NO304489B1 (no) | 1991-12-06 | 1992-12-04 | Mikroorganisme for deteksjon av tetracyklin efflukspumpehemmere og anvendelse av mikroorganismen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5789188A (enExample) |
| EP (1) | EP0547403A1 (enExample) |
| JP (1) | JP3329395B2 (enExample) |
| KR (1) | KR100245831B1 (enExample) |
| AU (1) | AU670551B2 (enExample) |
| CA (1) | CA2084404A1 (enExample) |
| NO (1) | NO304489B1 (enExample) |
| TW (1) | TW318189B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE40183E1 (en) | 1991-10-04 | 2008-03-25 | Wyeth Holdings Corporation | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
| US5494903A (en) | 1991-10-04 | 1996-02-27 | American Cyanamid Company | 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
| US5989832A (en) * | 1995-04-21 | 1999-11-23 | Microcide Pharmaceuticals, Inc. | Method for screening for non-tetracycline efflux pump inhibitors |
| US6068972A (en) | 1997-10-03 | 2000-05-30 | Trustees Of Tufts College | Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents |
| US6436694B1 (en) * | 1998-01-09 | 2002-08-20 | Cubist Pharmaceuticals, Inc. | Regulable gene expression in gram-positive bacteria |
| US6346391B1 (en) | 1999-07-22 | 2002-02-12 | Trustees Of Tufts College | Methods of reducing microbial resistance to drugs |
| GB0123401D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Forschungsstiftung | Methods of inducing gene expression |
| EP2361933A3 (en) | 2005-01-26 | 2012-05-02 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| GB0806803D0 (en) * | 2008-04-15 | 2008-05-14 | Scottish Biomedical Ltd | Reverse reporter assay |
| US9518283B1 (en) | 2012-02-27 | 2016-12-13 | Paradigm Diagnostics, Inc. | Selective enrichment media and uses thereof |
| CN110257471B (zh) * | 2019-06-06 | 2020-08-18 | 南京农业大学 | 利用生物传感器检测土壤中可提取态四环素类抗生素的试纸条及方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806529A (en) * | 1982-11-18 | 1989-02-21 | Trustees Of Tufts College, Tufts University | Tetracycline activity enhancement |
| US4911924A (en) * | 1987-04-17 | 1990-03-27 | University Of New Mexico | Induction of antibiotic hypersensitivity in tetracycline-resistance microorganisms |
| US5001230A (en) * | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
| DE69129429T2 (de) * | 1990-07-26 | 1998-09-24 | American Cyanamid Co | Zur Actinomyceten-DNS-Klonierung nützliches bifunktionelles Cosmid |
| EP0468220A3 (en) * | 1990-07-26 | 1992-09-23 | American Cyanamid Company | Cloning of the biosynthetic pathway genes for chlortetracycline production from streptomyces aureofaciens & their expression in steptomyces lividans |
-
1992
- 1992-04-08 TW TW081102693A patent/TW318189B/zh active
- 1992-11-23 EP EP92119888A patent/EP0547403A1/en not_active Withdrawn
- 1992-12-04 NO NO924705A patent/NO304489B1/no unknown
- 1992-12-04 JP JP35012692A patent/JP3329395B2/ja not_active Expired - Fee Related
- 1992-12-04 AU AU29896/92A patent/AU670551B2/en not_active Ceased
- 1992-12-04 CA CA002084404A patent/CA2084404A1/en not_active Abandoned
- 1992-12-05 KR KR1019920023449A patent/KR100245831B1/ko not_active Expired - Fee Related
-
1996
- 1996-05-13 US US08/644,931 patent/US5789188A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR100245831B1 (ko) | 2000-04-01 |
| NO924705L (no) | 1993-06-07 |
| TW318189B (enExample) | 1997-10-21 |
| AU2989692A (en) | 1993-06-10 |
| CA2084404A1 (en) | 1993-06-07 |
| US5789188A (en) | 1998-08-04 |
| JPH05317093A (ja) | 1993-12-03 |
| JP3329395B2 (ja) | 2002-09-30 |
| NO924705D0 (no) | 1992-12-04 |
| AU670551B2 (en) | 1996-07-25 |
| EP0547403A1 (en) | 1993-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Missiakas et al. | Modulation of the Escherichia coliσE (RpoE) heat‐shock transcription‐factor activity by the RseA, RseB and RseC proteins | |
| Claessen et al. | Control of the cell elongation–division cycle by shuttling of PBP1 protein in Bacillus subtilis | |
| Huisman et al. | Multiple defects in Escherichia coli mutants lacking HU protein | |
| Haldimann et al. | Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12 | |
| Ogawa et al. | Functional study of the novel multidrug efflux pump KexD from Klebsiella pneumoniae | |
| Bianchi et al. | Stress responses as a tool to detect and characterize the mode of action of antibacterial agents | |
| Pagès et al. | recX, a new SOS gene that is co-transcribed with the recA gene in Escherichia coli | |
| Bakkes et al. | Improved pEKEx2-derived expression vectors for tightly controlled production of recombinant proteins in Corynebacterium glutamicum | |
| Esquinas-Rychen et al. | Facilitation of bacteriophage lambda DNA injection by inner membrane proteins of the bacterial phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS) | |
| Clarke et al. | Point mutations in the transmembrane domain of DjlA, a membrane‐linked DnaJ‐like protein, abolish its function in promoting colanic acid production via the Rcs signal transduction pathway | |
| Andrews et al. | opp-lac operon fusions and transcriptional regulation of the Escherichia coli trp-linked oligopeptide permease | |
| Nieto et al. | The chromosomal relBE2 toxin–antitoxin locus of Streptococcus pneumoniae: characterization and use of a bioluminescence resonance energy transfer assay to detect toxin–antitoxin interaction | |
| EP0922106B1 (en) | Light emitting biosensor | |
| NO304489B1 (no) | Mikroorganisme for deteksjon av tetracyklin efflukspumpehemmere og anvendelse av mikroorganismen | |
| Chen et al. | Specificity determinants of conjugative DNA processing in the Enterococcus faecalis plasmid pCF10 and the Lactococcus lactis plasmid pRS01 | |
| Aleksandrzak-Piekarczyk et al. | Genetic characterization of the CcpA-dependent, cellobiose-specific PTS system comprising CelB, PtcB and PtcA that transports lactose in Lactococcus lactis IL1403 | |
| Snyder et al. | Enhanced export of beta-galactosidase fusion proteins in prlF mutants is Lon dependent | |
| Salah‐Bey et al. | Stress‐activated expression of a Streptomyces pristinaespiralis multidrug resistance gene (ptr) in various Streptomyces spp. and Escherichia coli | |
| US6475719B1 (en) | Determination of factors affecting gene regulation and/or gene replication | |
| Matavacas et al. | Bacillus subtilis forms twisted cells with cell wall integrity defects upon removal of the molecular chaperones DnaK and trigger factor | |
| Rees et al. | Phage for the detection of pathogenic bacteria | |
| US5384259A (en) | Construct and method for expression of tetracycline resistance genes in E. Coli | |
| Wolska et al. | Antibiotic susceptibility of Escherichia coli dnaK and dnaJ mutants | |
| CA2325602A1 (en) | Regulated target expression for screening | |
| Datta et al. | The mutation that makes Escherichia coli resistant to λ P gene-mediated host lethality is located within the DNA initiator gene dnaA of the bacterium |